Identification of Tumor Antigens by Using Proteomics
The recent progress of proteomics has opened new avenues for tumor-associated antigen discovery. Here, I describe a two-dimensional (2D), gel-based Western blot approach for screening and identification of proteins eliciting a humoral response in cancer. Sera from patients are used in 2D Western blot experiments for screening of autoantibodies, and the immunoreactive target proteins are subsequently identified by mass spectrometry. Applied to several types of cancer, this proteomic-based approach has revealed a high frequency of autoantibodies in sera from cancer patients and has led to the identification of novel tumor antigens. Relevant examples are described.
Key WordsAutoantibodies mass spectrometry proteomics two-dimensional (2D) Western blot tumor antigens
- 1.Happ, S. S. (1997) A Commotion in the Blood: Life, Death, and the Immune System. The Spoon Technology Series. Henry Holt and Company Inc., NY, NY.Google Scholar
- 10.Chen, Y. T. (2000) Cancer vaccine: identification of human tumor antigens by SEREX. Cancer J. Sci. Am. 6, s208–s217.Google Scholar
- 15.Le Naour, F., Misek, D. E., Krause, M. C., et al. (2001) Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin. Cancer Res. 11, 3328–3335.Google Scholar
- 17.Le Naour, F., Brichory, F., Misek, D. E., Bréchot, C., Hanash, S. M., and Beretta L. (2001) A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol. Cell Proteomics 1, 197–203.Google Scholar
- 28.Henash, S. M. (2003) The emerging field of protein microarrays. Proteomics 3 (special issue), 2075.Google Scholar